Neoadjuvant systemic therapy for hepatocellular carcinoma

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: March 1, 2024

Surgical resection and liver transplant remain the only curative therapies for most patients with hepatocellular carcinoma (HCC). Systemic therapy options have typically been ineffective, but recent advances, such as combination of immune checkpoint inhibitors targeted therapies, shown great promise. Neoadjuvant systemic in resectable or locally advanced HCC is under active investigation encouraging results small, early-phase trials. Many these completed ongoing trials include combinations (e.g. inhibitors, tyrosine kinase inhibitors), transarterial radiation. Despite early successes, larger evaluation long-term oncologic outcomes are needed to determine role neoadjuvant who may be eligible intent surgery transplant.

Language: Английский

---

Introductory Chapter: The Enigma of Hepatitis B Therapeutics

IntechOpen eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Language: Английский

---

Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma

Cancers, Journal Year: 2024, Volume and Issue: 16(10), P. 1852 - 1852

Published: May 12, 2024

Hepatocellular carcinoma (HCC) is the most common primary liver tumor in adults, and fourth leading cause of cancer-related deaths worldwide. While surgical ablative therapies remain standard care early localized disease, late presentation with advanced stages impaired hepatic function, or local recurrence following resection preclude operative management as sole treatment modality a subgroup patients. As such, systemic therapies, namely immunotherapy, have become an integral part HCC algorithm over past decade. agents, such atezolizumab/bevacizumab, well-established roles first-line therapy intermediate- advanced-stage HCC, role immunotherapy disease amenable to continues evolve. In this review, we will discuss current evidence aggregate impact context management, including its application neoadjuvant adjuvant settings.

Language: Английский

---

Osteoblastic Bone Reaction Developing During Treatment With Sintilimab and Bevacizumab in a Patient With KRAS ^G12V-Mutant Lung Adenocarcinoma

World Journal of Oncology, Journal Year: 2023, Volume and Issue: 14(6), P. 580 - 583

Published: Nov. 18, 2023

Osteoblastic bone reaction, the occurrence of new osteoblastic lesions, is a paradoxical phenomenon during treatment cancers and can be defined as disease progression or metastases. reactions usually occur in patients who receive treatments such chemotherapy hormonal targeted therapy; however, it difficult to differentiate them from an increase activity response therapy. Although reaction lung cancer has been described few reports, never reported with KRASG12V-mutant adenocarcinoma treated immunotherapy antiangiogenesis. Here, we describe case 77-year-old male whose was found sintilimab bevacizumab. We showed course well systematic imaging manifestations discussed their mechanisms.

Language: Английский

---

The Sweet and Sour of Glycan Targeting in Cancer

Interdisciplinary cancer research, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

---